A Randomized Phase 2 Trial of 177Lu Radiolabeled Anti-PSMA Monoclonal Antibody J591 in Patients With High-Risk Castrate, Biochemically Relapsed Prostate Cancer
Technical Report,17 Aug 2015,16 Aug 2016
CORNELL UNIV MEDICAL COLL (WEILL) NEW YORK NEW YORK United States
Pagination or Media Count:
Clinical trial has received WCMC IRB and CTSC approval with enrollment of initial 6 subjects at WCMC. An additional 38 subjects enrolled 29 treated at participating sub-sites. Reports submitted to WCMC DSMB in December 2014 with approval to proceed without modifications.
- Medicine and Medical Research